Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

THERMO FISHER SCIENTIFIC

(TMO)
  Report
Delayed Nyse  -  03:49 2022-12-06 pm EST
550.06 USD   -1.28%
08:01aThermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions
BU
11/29Transcript : Thermo Fisher Scientific Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Nov-29-2022 10:30 AM
CI
11/29Barclays Cuts Price Target on Thermo Fisher to $570 From $575, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Collaborates with Taiwan Precision Medicine Initiative to Genotype 1 Million People in Taiwan

09/13/2022 | 08:00am EST

Thermo Fisher Scientific partnered with the Taiwan Precision Medicine Initiative (TPMI) to advance the next phase of the large-scale predictive genomics study and support its goal of genotyping 1 million people in Taiwan. TPMI reached the milestone of enrolling more than 500,000 participants in July, making it the large study of its kind outside of the United States and Europe. Launched by Academia Sinica and a network of hospital systems throughout the country in 2019, the predictive genomics project aims to optimize the future of healthcare by enabling clinicians toward establishing future guidelines to manage patients at high risk for serious diseases such as cancer, cardiovascular, neurodegenerative and other disorders as well as provide personalized drug prescription based on pharmacogenetic factors.

TPMI initially collaborated with Thermo Fisher to design a custom genotyping research array for identifying genetic factors that may increase the risk of certain diseases. In the next phase of the project, TPMI will work with Thermo Fisher to optimize the Axiom genotyping platform with the aim of translating the results to clinical use and expanding the development of disease risk prediction algorithms for at least 20 common diseases relevant to Han Chinese people, approximately 18% of the global population. The Axiom custom array developed for TPMI contains more than 700,000 genetic markers selected to capture variants of interest.

Initial TPMI analysis revealed 83 potentially clinically relevant genes associated with disease risk or drug reactions. Thermo Fisher currently supports several large-scale population studies globally, including UK Biobank, FinnGen Precision Medicine Study, Qatar Genome Program and the U.S. Department of Veterans Affairs' Million Veteran Program (MVP). Each of these initiatives leverages the company's Applied Biosystems Axiom genotyping arrays and customization services, which have helped to drive predictive genomic studies for more than a decade.


ę S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
08:01aThermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Ne..
BU
11/29Transcript : Thermo Fisher Scientific Inc. Presents at 5th Annual Evercore IS..
CI
11/29Barclays Cuts Price Target on Thermo Fisher to $570 From $575, Maintains Overweight Rat..
MT
11/21Thermo Fisher Scientific Issues 1.25 Billion Euros of 2026, 2034 Notes
MT
11/21Thermo Fisher Scientific Inc. : Entry into a Material Definitive Agreement, Other Events, ..
AQ
11/21Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference
BU
11/18Insider Sell: Thermo Fisher Scientific
MT
11/16Thermo Fisher Scientific : Introduces Rapid Point-of-Care RT-PCR Flu A/Flu B Test
PU
11/16Thermo Fisher Scientific to Seek Acquisitions
CI
11/16Thermo Fisher Scientific Introduces All-In-One AAV Production System for Scalable Gene ..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 857 M - -
Net income 2022 6 919 M - -
Net Debt 2022 24 995 M - -
P/E ratio 2022 31,8x
Yield 2022 0,21%
Capitalization 220 B 220 B -
EV / Sales 2022 5,58x
EV / Sales 2023 5,47x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 557,21 $
Average target price 615,69 $
Spread / Average Target 10,5%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors